Manchester Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $177K | Sell |
396
-9
| -2% | -$4.2K | 0.03% | 287 |
|
|
2025
Q4 | $184K | Buy |
405
+141
| +53% | +$60.8K | 0.03% | 281 |
|
|
2025
Q3 | $103K | Sell |
264
-242
| -48% | -$101K | 0.01% | 408 |
|
|
2025
Q2 | $225K | Sell |
506
-20
| -4% | -$9.22K | 0.03% | 319 |
|
|
2025
Q1 | $255K | Sell |
526
-174
| -25% | -$81.1K | 0.03% | 299 |
|
|
2024
Q4 | $282K | Sell |
700
-31
| -4% | -$14.4K | 0.03% | 289 |
|
|
2024
Q3 | $340K | Buy |
731
+31
| +4% | +$14.9K | 0.04% | 266 |
|
|
2024
Q2 | $328K | Buy |
700
+291
| +71% | +$126K | 0.04% | 254 |
|
|
2024
Q1 | $171K | Sell |
409
-16
| -4% | -$6.76K | 0.02% | 330 |
|
|
2023
Q4 | $173K | Buy |
425
+230
| +118% | +$85K | 0.02% | 301 |
|
|
2023
Q3 | $67.8K | Buy |
195
+136
| +231% | +$47.6K | 0.01% | 386 |
|
|
2023
Q2 | $20.8K | Buy |
59
+5
| +9% | +$1.69K | ﹤0.01% | 497 |
|
|
2023
Q1 | $17K | Hold |
54
| – | – | ﹤0.01% | 509 |
|
|
2022
Q4 | $15.6K | Sell |
54
-4
| -7% | -$1.22K | ﹤0.01% | 432 |
|
|
2022
Q3 | $17K | Hold |
58
| – | – | ﹤0.01% | 417 |
|
|
2022
Q2 | $16K | Hold |
58
| – | – | ﹤0.01% | 441 |
|
|
2022
Q1 | $15K | Hold |
58
| – | – | ﹤0.01% | 500 |
|
|
2021
Q4 | $13K | Buy |
58
+4
| +7% | +$778 | ﹤0.01% | 537 |
|
|
2021
Q3 | $10K | Hold |
54
| – | – | ﹤0.01% | 594 |
|
|
2021
Q2 | $11K | Hold |
54
| – | – | ﹤0.01% | 492 |
|
|
2021
Q1 | $12K | Hold |
54
| – | – | ﹤0.01% | 475 |
|
|
2020
Q4 | $13K | Sell |
54
-4
| -7% | -$918 | ﹤0.01% | 466 |
|
|
2020
Q3 | $16K | Buy |
58
+4
| +7% | +$1.1K | ﹤0.01% | 398 |
|
|
2020
Q2 | $16K | Hold |
54
| – | – | ﹤0.01% | 443 |
|
|
2020
Q1 | $13K | Hold |
54
| – | – | ﹤0.01% | 454 |
|
|
2019
Q4 | $12K | Hold |
54
| – | – | ﹤0.01% | 459 |
|
|
2019
Q3 | $9K | Hold |
54
| – | – | ﹤0.01% | 464 |
|
|
2019
Q2 | $10K | Hold |
54
| – | – | ﹤0.01% | 489 |
|
|
2019
Q1 | $10K | Buy |
+54
| New | +$9.97K | ﹤0.01% | 566 |
|
|
2015
Q1 | – | Sell |
-134
| Closed | -$16K | – | 890 |
|
|
2014
Q4 | $16K | Hold |
134
| – | – | ﹤0.01% | 917 |
|
|
2014
Q3 | $15K | Hold |
134
| – | – | ﹤0.01% | 916 |
|
|
2014
Q2 | $13K | Buy |
134
+94
| +235% | +$6.59K | ﹤0.01% | 905 |
|
|
2014
Q1 | $3K | Sell |
40
-14
| -26% | -$1.11K | ﹤0.01% | 949 |
|
|
2013
Q4 | $4K | Buy |
54
+11
| +26% | +$766 | ﹤0.01% | 861 |
|
|
2013
Q3 | $3K | Buy |
+43
| New | +$3.42K | ﹤0.01% | 933 |
|
Other funds holding VRTX
VCM
VPM
Manchester Capital Management's VRTX Position: Q1 2026 in Review
Manchester Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, selling an estimated $4.2K and leaving 396 shares worth $177K. The position accounts for 0.03% of the portfolio, ranked #287.
Manchester Capital Management first reported a position in VRTX in Q3 2013 and has held it in 35 quarters since. The position peaked at $340K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Manchester Capital Management held 396 shares of Vertex Pharmaceuticals worth $177K as of Q1 2026.
- Manchester Capital Management sold 9 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2K.
- Vertex Pharmaceuticals made up 0.03% of Manchester Capital Management's portfolio in Q1 2026, its #287 holding.
- Manchester Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 35 quarters since.
- Manchester Capital Management's Vertex Pharmaceuticals position peaked at $340K in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.